Vantictumab
Catalogue number:
HY-P9974-5mg
Supplier:
Size:
5 mg
Product is available in:
Applications:
Cancer-programmed cell death
Target:
Wnt
Alternative Names:
OMP-18R5
- Data sheet: View or download
- MSDS: View or download
- Protocol: View or download
Product Description:
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2][3].